Eastman Kodak NYSE: KODK reported higher third-quarter revenue, gross profit and net income, with growth in its Advanced Materials and Chemicals segment offsetting lower sales in its Print business.
ROCHESTER, N.Y.--(BUSINESS WIRE)--Eastman Kodak Company today announced the expansion of its KODAK PHARMACEUTICALS portfolio with the addition of KODAK® Normal Saline, 0.9%. The company also introduced a new U.S.-based online store designed to simplify purchasing for pharmaceutical, biotech, and life science customers.
Eastman Kodak is executing a credible turnaround, with strong revenue and margin improvements, particularly in its Advanced Materials & Chemicals (AM&C) segment. KODK posted 18% y/y revenue growth in Q2 '26, with AM&C up 40% and gross margins expanding 700 bps to 26.4%, signaling operational momentum. The balance sheet has strengthened with $290 million in cash and $110 million in debt, though cash flow remains a concern due to inventory buildup and higher silver prices.
Counterpoint Mutual Funds LLC acquired a new position in Eastman Kodak Company (NYSE: KODK) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 81,274 shares of the technology company's stock, valued at approximately $777,000. Counterpoint Mutual Funds LLC
Eastman Kodak (NYSE: KODK) reported higher second-quarter revenue, profit and operational EBITDA, marking its fourth consecutive quarter of year-over-year gains in those measures, as growth in its Advanced Materials and Chemicals and Print businesses helped offset higher commodity costs. For the quarter ended June 30, Kodak posted revenue of $311 million, up 18% from $263 million